Cabaletta Bio, Inc.
CABA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$1.46
KIRA · Stoqly’s AI analyst, in plain words
- Cabaletta Bio, Inc. lost $168M in fiscal 2025.
- Free cash flow was −$132M in fiscal 2025, — of revenue.
Market cap
$220M
P/E
—
Revenue
—
Net income
−$168M
Free cash flow
−$132M
Operating margin
—
Cabaletta Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$168M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cabaletta Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- Cabaletta Bio, Inc.
- CIK
- 0001759138
Cabaletta Bio, Inc. · CABA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$46.3M | −$53.0M | −$67.7M | −$116M | −$168M |
| Diluted EPS | −$1.80 | −$1.81 | −$1.65 | −$2.34 | −$2.10 |
| Cash | |||||
| Cash from operations | −$34.1M | −$46.4M | −$53.5M | −$88.2M | −$131M |
| Capital expenditure | $1.2M | $2.5M | $0.7M | $2.2M | $1.2M |
| Free cash flow | −$35.3M | −$48.8M | −$54.2M | −$90.4M | −$132M |
| Debt and strength | |||||
| Cash and short-term investments | $122M | $107M | $241M | $164M | $134M |
| Shareholders' equity | $118M | $105M | $236M | $152M | $112M |
| Current ratio | 14.9x | 11.5x | 15.3x | 6.2x | 2.8x |
| Interest coverage | — | — | — | −167.3x | −85.9x |
| Returns and quality | |||||
| Return on equity | −40.7% | −47.6% | −39.7% | −59.6% | −127.0% |
| Return on tangible equity | −39.2% | −50.7% | −28.7% | −76.1% | −149.8% |
| Altman Z'' | 15.4 | 6.7 | 15.1 | −0.9 | −11.5 |
Insiders bought, 12 months
$0.3M
8 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cabaletta Bio, Inc. · CABA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.46 a share, the company is worth $220M.
Source: SEC EDGAR XBRL filings (CIK 0001759138). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.